BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)
Ipilimumab is a CTLA-4 blocking monoclonal antibody which demonstrated improvement in overall survival compared to vaccine as well as chemotherapy for patients with unresectable or metastatic melanoma [87, 88]. Two large-scale Phase III trials are underway examining the value of adjuvant ipilimumab therapy, EORTC 18071 trial comparing adjuvant ipilimumab to placebo and E1609 is comparing two different doses of ipilimumab to high-dose IFNα. Accrual to these trials is now complete and results are eagerly anticipated.
[contact-form-7 id=»5168″ title=»Контактная форма 1″]